Value of Thyroid Stimulating Hormone Inhibition Therapy in Differentiated Thyroid Carcinoma_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

MA Junfeng ¹ , TANG Bo ² , LI Tiehan ² , ZHANG Jie ²

1.Department of Tumor， The Second Affiliated Hospital of Kunming Medical College， Kunming 650101， China;;
2.Department of General Surgery， The Second Affiliated Hospital of Kunming Medical College， Kunming 650101， China;

Corresponding author：

Keywords：

Differentiated thyroid carcinoma; Thyroid stimulating hormone inhibition therapy; Thyroid hormone replacement therapy; Recurrence rate; Metastasis rate

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the value of thyroid stimulating hormone (TSH) inhibition therapy in postoperative patients with differentiated thyroid carcinoma. Methods One hundred and six patients with differentiated thyroid carcinoma after total or near-total thyroidectomy were divided into two groups: TSH inhibition therapy group and thyroid hormone replacement therapy group. The non-recurrence and (or) non-metastasis rate in two groups was analyzed retrospectively by Wilcoxon statistical analysis. Results The non-recurrence and (or) non-metastasis rate of 3-， 5- and 10-year in TSH inhibition therapy group were 98.31%， 92.41% and 75.45% respectively， and were higher than those (93.57%， 84.18% and 52.06% respectively) in thyroid hormone replacement therapy group （P=0.046 5）. Conclusion TSH inhibition therapy after total or near-total thyroidectomy may be an essential treatment for differentiated thyroid carcinoma patients.

Citation： MA Junfeng,TANG Bo,LI Tiehan,ZHANG Jie. Value of Thyroid Stimulating Hormone Inhibition Therapy in Differentiated Thyroid Carcinoma. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2009, 16(5): 348-350. doi: Copy

1.	Williams ED. Mechanisms and pathogenesis of thyroid cancer in animals and man [Ｊ]. Mutat Res, 1995; 333(1-2): 123-129.
2.	Mazzaferri EL. An overview of the management of papillary and follicular thyroid carcinoma [Ｊ]. Thyroid, 1999; 9(5): 421-427.
3.	郑泽霖，盖宝东，孙辉. 分化型甲状腺癌手术范围探讨 [Ｊ]. 中国普外基础与临床杂志, 2004; 11(6): 479-480.
4.	Manzone TA, Dam HQ, Intenzo CM, et al. Postoperative management of thyroid carcinoma [Ｊ]. Surg Oncol Clin N Am, 2008; 17(1): 197-218.
5.	Sherman SI. Thyroid carcinoma [Ｊ]. Lancet, 2003; 361(9356): 501-511.
6.	薛绪潮，方国恩. 甲状腺癌的内分泌治疗 [Ｊ]. 中国实用外科杂志， 2004; 24(10): 631-632.
7.	Shiba E. Diagnosis and treatment of differentiated thyroid carcinoma [Ｊ]. Nippon Geka Gakkai Zasshi, 2005; 106(8): 459-462.
8.	Cooper DS, Specker B, Ho M, et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry [Ｊ]. Thyroid, 1998; 8(9): 737-744.
9.	李小毅. 甲状腺球蛋白在分化型甲状腺癌诊治中的作用 [Ｊ]. 中国普外基础与临床杂志, 2006; 13(3): 265-267.
10.	Spencer CA, Wang CC. Thyroglobulin measurement. Techniques, clinical benefits, and pitfalls [Ｊ]. Endocrinol Metab Clin North Am, 1995; 24(4): 841-863.
11.	Miyakawa M. Effects of thyrotropin-suppressive therapy in patients with well-differentiated thyroid carcinoma [Ｊ]. Nippon Rinsho, 2007; 65(11): 2073-2077.
12.	Heemstra KA, Hamdy NA, Romijn JA， et al. The effects of thyrotropin-suppressive therapy on bone metabolism in patients with well-differentiated thyroid carcinoma [Ｊ]. Thyroid, 2006; 16(6): 583-591.
13.	Bartalena L, Bogazzi F, Martino E. Adverse effects of thyroid hormone preparations and antithyroid drugs [Ｊ]. Drug Saf， 1996; 15(1): 53-63.

1. Williams ED. Mechanisms and pathogenesis of thyroid cancer in animals and man [Ｊ]. Mutat Res, 1995; 333(1-2): 123-129.
2. Mazzaferri EL. An overview of the management of papillary and follicular thyroid carcinoma [Ｊ]. Thyroid, 1999; 9(5): 421-427.
3. 郑泽霖，盖宝东，孙辉. 分化型甲状腺癌手术范围探讨 [Ｊ]. 中国普外基础与临床杂志, 2004; 11(6): 479-480.
4. Manzone TA, Dam HQ, Intenzo CM, et al. Postoperative management of thyroid carcinoma [Ｊ]. Surg Oncol Clin N Am, 2008; 17(1): 197-218.
5. Sherman SI. Thyroid carcinoma [Ｊ]. Lancet, 2003; 361(9356): 501-511.
6. 薛绪潮，方国恩. 甲状腺癌的内分泌治疗 [Ｊ]. 中国实用外科杂志， 2004; 24(10): 631-632.
7. Shiba E. Diagnosis and treatment of differentiated thyroid carcinoma [Ｊ]. Nippon Geka Gakkai Zasshi, 2005; 106(8): 459-462.
8. Cooper DS, Specker B, Ho M, et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry [Ｊ]. Thyroid, 1998; 8(9): 737-744.
9. 李小毅. 甲状腺球蛋白在分化型甲状腺癌诊治中的作用 [Ｊ]. 中国普外基础与临床杂志, 2006; 13(3): 265-267.
10. Spencer CA, Wang CC. Thyroglobulin measurement. Techniques, clinical benefits, and pitfalls [Ｊ]. Endocrinol Metab Clin North Am, 1995; 24(4): 841-863.
11. Miyakawa M. Effects of thyrotropin-suppressive therapy in patients with well-differentiated thyroid carcinoma [Ｊ]. Nippon Rinsho, 2007; 65(11): 2073-2077.
12. Heemstra KA, Hamdy NA, Romijn JA， et al. The effects of thyrotropin-suppressive therapy on bone metabolism in patients with well-differentiated thyroid carcinoma [Ｊ]. Thyroid, 2006; 16(6): 583-591.
13. Bartalena L, Bogazzi F, Martino E. Adverse effects of thyroid hormone preparations and antithyroid drugs [Ｊ]. Drug Saf， 1996; 15(1): 53-63.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Value of Thyroid Stimulating Hormone Inhibition Therapy in Differentiated Thyroid Carcinoma

Abstract Full text Figures/Tables Video References Cited by

Format

Content